Faculty profile

Janet Dancey

ResearcherQueen's University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Queen's University directory, so their courses may be missing. Find their university profile.

Janet Dancey

Researcher

Health Sciences

Queen's University

Kingston, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
7 publications in the last five years, latest in 2026.
Senior (last) author on 4 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

233

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Melanoma Randomized Controlled Trial Fecal Microbiota Transplant Microbiome Multicentre Phase Ii Progression-Free Survival Cancer

Latest papers

(Neo)adjuvant approvals for solid tumors by the US Food and Drug Administration 2010-2023.
Journal of the National Cancer Institute · 2026
CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).
Cancer treatment and research communications · 2026 · senior author
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial
EClinicalMedicine · 2025 · senior author

All 22 publications

Latest funding

Fecal microbiota transplantation in combination with immune checkpoint blockade in patients with advanced melanoma: A randomized phase II trial
CIHR · 2023 · Nominated PI
$1,786,273
Melanoma Margins Trial II - A Phase III, Multi-centre Randomized Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC stage II Primary Cutaneous Melanoma (MelMarT-II)
CIHR · 2019 · Nominated PI
$1,303,560
Canadian Cell Therapies Workshop 2019
CIHR · 2018 · Co-investigator
$10,000

All 4 grants and awards

22 publications.

(Neo)adjuvant approvals for solid tumors by the US Food and Drug Administration 2010-2023.

Valiente CM, Mittal A, Tu D, Amir E, Pater J, Dancey J, Gyawali B, Booth CM, Wilson BE

Journal of the National Cancer Institute2026

DOI: 10.1093/jnci/djag133 PMID: 42714223

CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).

MacKay HJ, Tinker AV, Nelson BH, Zamarin D, Odunsi AO, Lheureux S, Ellard S, Smrke A, Gaudreau PO, Faulkner T, Upadhaya S, Zhou A, Tu W, Dancey J

Cancer treatment and research communications2026Senior author

DOI: 10.1016/j.ctarc.2026.101260 PMID: 42225005

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial

Gupta AA, Tinker A, Jonker D, Jamal R, Hirte H, Winquist EW, Chu Q, Kollmannsberger C, Wong R, Alcindor T

EClinicalMedicine20255 citationsSenior author

DOI: 10.1016/j.eclinm.2024.102991

Correlative Science in the Cooperative Group System: Re-Engineering for Success.

O'Dwyer PJ, Wolmark N, Hawkins DS, Schnall M, Dancey J, Blanke C, Mannel R, Galanis E, Le QT

Journal of clinical oncology : official journal of the American Society of Clinical Oncology2024

DOI: 10.1200/jco.24.00527 PMID: 39288338

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, Wheatley-Price P, Laurie SA, Levy B, Brahmer JR

Nature Medicine2023175 citationsSenior author

DOI: 10.1038/s41591-023-02598-9

CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC.

Leighl NB, Laurie SA, Goss GD, Hughes BGM, Stockler M, Tsao MS, Hwang DM, Joubert P, Kulkarni S, Blais N, Joy AA, Mates M, Rana P, Yadav SK, Underhill C, Lee C, Bradbury PA, Hiltz A, Dancey J, Ding K, Vera-Badillo F, Canadian Cancer Trials Group Lung Disease Site and the Australasian Lung Cancer Trials Group

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2022

DOI: 10.1016/j.jtho.2021.10.023 PMID: 34800700

Addressing the Barriers to Clinical Trials Accrual in Community Cancer Centres Using a National Clinical Trials Navigator:A Cross-Sectional Analysis.

Hamm C, Cavallo-Medved D, Moudgil D, McGrath L, Huang J, Li Y, Stratton TW, Robinson T, Naccarato K, Sundquist S, Dancey J

Cancer control : journal of the Moffitt Cancer Center2022Senior author

DOI: 10.1177/10732748221130164 PMID: 36165718

Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms.

Saini KS, de Las Heras B, Plummer R, Moreno V, Romano M, de Castro J, Aftimos P, Fredriksson J, Bhattacharyya GS, Olivo MS, Schiavon G, Punie K, Garcia-Foncillas J, Rogata E, Pfeiffer R, Orbegoso C, Morrison K, Curigliano G, Chin L, Saini ML, Rekdal Ø, Anderson S, Cortes J, Leone M, Dancey J, Twelves C, Awada A

JCO global oncology2020

DOI: 10.1200/go.20.00346 PMID: 32897732

RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.

Litière S, Isaac G, De Vries EGE, Bogaerts J, Chen A, Dancey J, Ford R, Gwyther S, Hoekstra O, Huang E, Lin N, Liu Y, Mandrekar S, Schwartz LH, Shankar L, Therasse P, Seymour L, RECIST Working Group

Journal of clinical oncology : official journal of the American Society of Clinical Oncology2019

DOI: 10.1200/jco.18.01100 PMID: 30860949

Conducting clinical trials-costs, impacts, and the value of clinical trials networks: A scoping review.

Bentley C, Cressman S, van der Hoek K, Arts K, Dancey J, Peacock S

Clinical trials (London, England)2019

DOI: 10.1177/1740774518820060 PMID: 30628466

Something wrong or missing on this profile? Suggest a correction

Janet Dancey

Research

Latest papers

Latest funding

(Neo)adjuvant approvals for solid tumors by the US Food and Drug Administration 2010-2023.

CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021).

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial

Correlative Science in the Cooperative Group System: Re-Engineering for Success.

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC.

Addressing the Barriers to Clinical Trials Accrual in Community Cancer Centres Using a National Clinical Trials Navigator:A Cross-Sectional Analysis.

Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms.

RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.

Conducting clinical trials-costs, impacts, and the value of clinical trials networks: A scoping review.

Fecal microbiota transplantation in combination with immune checkpoint blockade in patients with advanced melanoma: A randomized phase II trial

Melanoma Margins Trial II - A Phase III, Multi-centre Randomized Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC stage II Primary Cutaneous Melanoma (MelMarT-II)

Canadian Cell Therapies Workshop 2019

Future NCIC Clinical Trials Group Activities in Oncologic Translational Research Addressing Strategies in Personalized Medicine

Frequent collaborators

Lesley Seymour

Adrian Sacher

Susan Marlin

Anna Tinker

Caroline Hamm

Stephanie Lheureux

Eitan Amir

Sonya Cressman

Derek Jonker

John Hilton

Stuart Peacock

Paul Wheatley-Price

Rosalyn Juergens

Sebastien Hotte

Mark Norman Levine

Holger Hirte

Ming-Sound Tsao

Stuart Peacock

Michael Brundage